期刊
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
卷 33, 期 4, 页码 155-165出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/cbr.2018.2451
关键词
internal dosimetry; Monte Carlo; radiopharmaceuticals; targeted radionuclide therapy
类别
资金
- NIH [R01 CA 158800, 9U54TR000021, R21 CA198392-01]
This work describes the development and validation of a patient-specific Monte Carlo internal dosimetry platform called RAPID (Radiopharmaceutical Assessment Platform for Internal Dosimetry). RAPID utilizes serial PET/CT or SPECT/CT images to calculate voxelized three-dimensional (3D) internal dose distributions with the Monte Carlo code Geant4. RAPID's dosimetry calculations were benchmarked against previously published S-values and specific absorbed fractions (SAFs) calculated for monoenergetic photon and electron sources within the Zubal phantom and for S-values calculated for a variety of radionuclides within spherical tumor phantoms with sizes ranging from 1 to 1000g. The majority of the S-values and SAFs calculated in the Zubal Phantom were within 5% of the previously published values with the exception of a few 10keV photon SAFs that agreed within 10%, and one value within 16%. The S-values calculated in the spherical tumor phantoms agreed within 2% for Lu-177, I-131, I-125, F-18, and Cu-64, within 3.5% for At-211 and Bi-213, within 6.5% for Sm-153, In-111, Zr-89, and Ra-223, and within 9% for Y-90, Ga-68, and I-124. In conclusion, RAPID is capable of calculating accurate internal dosimetry at the voxel-level for a wide variety of radionuclides and could be a useful tool for calculating patient-specific 3D dose distributions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据